Mitral valve repair for degenerative disease with leaflet prolapse: to improve long-term outcomes

2009 ◽  
Vol 57 (1) ◽  
pp. 10-21 ◽  
Author(s):  
Takashi Miura ◽  
Kiyoyuki Eishi ◽  
Siro Yamachika ◽  
Koji Hashizume ◽  
Kentaro Yamane ◽  
...  
2014 ◽  
Vol 148 (4) ◽  
pp. 1400-1406 ◽  
Author(s):  
Puja Gaur ◽  
Tsuyoshi Kaneko ◽  
Siobhan McGurk ◽  
James D. Rawn ◽  
Ann Maloney ◽  
...  

2006 ◽  
Vol 131 (2) ◽  
pp. 364-370 ◽  
Author(s):  
Michele De Bonis ◽  
Roberto Lorusso ◽  
Elisabetta Lapenna ◽  
Samer Kassem ◽  
Giuseppe De Cicco ◽  
...  

2019 ◽  
Vol 3 (sup1) ◽  
pp. 164-164
Author(s):  
Hiroshi Seki ◽  
Dai Une ◽  
Mimiko Tabata ◽  
Togo Norimatsu ◽  
Atsushi Kurata

Circulation ◽  
2001 ◽  
Vol 104 (suppl_1) ◽  
Author(s):  
Dania Mohty ◽  
Thomas A. Orszulak ◽  
Hartzell V. Schaff ◽  
Jean-Francois Avierinos ◽  
Jamil A. Tajik ◽  
...  

Background Mitral regurgitation (MR) due to mitral valve prolapse (MVP) is often treatable by surgical repair. However, the very long-term (>10-year) durability of repair in both anterior leaflet prolapse (AL-MVP) and posterior leaflet prolapse (PL-MVP) is unknown. Methods and Results In 917 patients (aged 65±13 years, 68% male), surgical correction of severe isolated MR due to MVP (679 repairs and 238 replacements [MVRs]) was performed between 1980 and 1995. Survival after repair was better than survival after MVR for both PL-MVP (at 15 years, 41±5% versus 31±6%, respectively; P =0.0003) and AL-MVP (at 14 years, 42±8% versus 31±5%, respectively; P =0.003). In multivariate analysis adjusting for predictors of survival, repair was independently associated with lower mortality in PL-MVP (adjusted risk ratio [RR] 0.61, 95% CI 0.44 to 0.85; P =0.0034) and in AL-MVP (adjusted RR 0.67, 95% CI 0.47 to 0.96; P =0.028). The reoperation rate was not different after repair or MVR overall (at 19 years, 20±5% for repair versus 23±5% for MVR; P =0.4) or separately in PL-MVP ( P =0.3) or AL-MVP ( P =0.3). However, the reoperation rate was higher after repair of AL-MVP than after repair of PL-MVP (at 15 years, 28±7% versus 11±3%, respectively; P =0.0006). From the 1980s to the 1990s, the RR of reoperation after repair of AL-MVP versus PL-MVP did not change (RR 2.5 versus 2.7, respectively; P =0.58), but the absolute rate of reoperation decreased similarly in PL-MVP and AL-MVP (at 10 years, from 10±3% to 5±2% and from 24±6% to 10±2%, respectively; P =0.04). Conclusions In severe MR due to MVP, mitral valve repair compared with MVR provides improved very long-term survival after surgery for both AL-MVP and PL-MVP. Reoperation is similarly required after repair or replacement but is more frequent after repair of AL-MVP. Recent improvement in long-term durability of repair suggests that it should be the preferred mode of surgical correction of MVP whether it affects anterior or posterior leaflets and is an additional incentive for early surgery of severe MR due to MVP.


2014 ◽  
Vol 148 (2) ◽  
pp. 454-460 ◽  
Author(s):  
Hunaid A. Vohra ◽  
Robert N. Whistance ◽  
Jawad Hechadi ◽  
Laurent de Kerchove ◽  
Hannah Fuller ◽  
...  

2018 ◽  
Vol 26 (5) ◽  
pp. 783-789 ◽  
Author(s):  
Anton Tomšič ◽  
Yasmine L Hiemstra ◽  
Stephanie L van der Pas ◽  
Hein Putter ◽  
Michel I M Versteegh ◽  
...  

2019 ◽  
Vol 35 (1) ◽  
pp. 11-20 ◽  
Author(s):  
Ayse Cetinkaya ◽  
Stephanie Bär ◽  
Stefan Hein ◽  
Karin Bramlage ◽  
Peter Bramlage ◽  
...  

2020 ◽  
pp. 021849232097076
Author(s):  
Somchai Waikittipong

Aim This retrospective study was undertaken to evaluate the long-term outcomes of mitral valve repair in rheumatic patients. Methods From 2003 to 2019, 151 patients (mean age 26.5 ± 14.9 years; 68.9% female) underwent mitral valve repair. Fifty-three (35.1%) had atrial fibrillation, and 79 (52.3%) were in New York Heart Association class III/IV. Pure mitral regurgitation was present in 109 (72.2%) patients, pure stenosis in 9 (6%), and mixed regurgitation and stenosis in 33. Results Three (2%) patients died postoperatively and 4 (2.6%) were lost during follow-up. Mean follow-up was 90.5 ± 55.6 months. There were 22 (14.8%) late deaths. Actuarial survival at 5, 10, and 15 years was 90.7% ± 2.5%, 83.5% ± 3.6%, and 76.5 ± 6.1%, respectively. Twelve (8.5%) patients underwent reoperation. Freedom from reoperation at 5, 10, and 15 years was 96.1% ± 1.7%, 89.8% ± 3.2%, and 82.3% ± 6.1%, respectively. Forty-two (29.2%) patients developed recurrent mitral regurgitation. Freedom from recurrence of mitral regurgitation at 5, 10, and 15 years was 70.9% ± 4.3%, 56% ± 5.9%, and 53.3% ± 6.4%, respectively. Eighty-one (56.6%) patients were and free from all events during follow-up. Freedom from all events at 5, 10, and 15 years was 64.8% ± 4.1%, 48.6% ± 5.3%, and 43.7% ± 5.8%, respectively. Conclusions Although rheumatic mitral valve repair is associated with late recurrence of mitral regurgitation, it has benefits in selected patients, especially children and young patients who want to avoid the lifelong risks of anticoagulation. Long-term follow-up is essential in these patients.


Sign in / Sign up

Export Citation Format

Share Document